Yudai Uehira, Hiroaki Ueno, Junki Miyamoto, Ikuo Kimura, Yohei Ishizawa, Hiroshi Iijima, Shota Muroga, Toru Fujita, Soichi Sakai, Yoshishige Samukawa, Yuri Tanaka, Shinya Murayama, Hideyuki Sakoda, Masamitsu Nakazato
Orlistat, an anti-obesity agent, inhibits the metabolism and absorption of dietary fat by inactivating pancreatic lipase in the gut. The effect of orlistat on the gut microbiota of Japanese individuals with obesity is unknown. This study aimed to explore the effects of orlistat on the gut microbiota and fatty acid metabolism of Japanese individuals with obesity. Fourteen subjects with visceral fat obesity (waist circumference ≥85 cm) took orlistat orally at a dose of 60 mg, 3 times a day for 8 weeks...
September 5, 2023: Obesity Research & Clinical Practice